8vjp: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Histidine-covalent stapled alpha-helical peptide (155H1) targeting hMcl-1== | |||
<StructureSection load='8vjp' size='340' side='right'caption='[[8vjp]], [[Resolution|resolution]] 1.13Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[8vjp]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Synthetic_construct Synthetic construct]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8VJP OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8VJP FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.13Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=A1AJD:(4Z)-oct-4-en-1-ol'>A1AJD</scene>, <scene name='pdbligand=A1AJE:(S~1~R)-3-carbamoyl-4-methoxybenzene-1-sulfinic+acid'>A1AJE</scene>, <scene name='pdbligand=ACY:ACETIC+ACID'>ACY</scene>, <scene name='pdbligand=NH2:AMINO+GROUP'>NH2</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8vjp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8vjp OCA], [https://pdbe.org/8vjp PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8vjp RCSB], [https://www.ebi.ac.uk/pdbsum/8vjp PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8vjp ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[https://www.uniprot.org/uniprot/MCL1_HUMAN MCL1_HUMAN] Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis.<ref>PMID:10766760</ref> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Several novel and effective cysteine targeting (Cys) covalent drugs are in clinical use. However, the target area containing a druggable Cys residue is limited. Therefore, methods for creating covalent drugs that target different residues are being looked for; examples of such ligands include those that target the residues lysine (Lys) and tyrosine (Tyr). Though the histidine (His) side chain is more frequently found in protein binding locations and has higher desirable nucleophilicity, surprisingly limited research has been done to specifically target this residue, and there are not many examples of His-targeting ligands that have been rationally designed. In the current work, we created novel stapled peptides that are intended to target hMcl-1 His 252 covalently. We describe the in vitro (biochemical, NMR, and X-ray) and cellular design and characterization of such agents. Our findings further suggest that the use of electrophiles to specifically target His residues is warranted. | |||
Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1.,Alboreggia G, Udompholkul P, Baggio C, Muzzarelli K, Assar Z, Pellecchia M J Med Chem. 2024 May 2. doi: 10.1021/acs.jmedchem.4c00277. PMID:38695666<ref>PMID:38695666</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 8vjp" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | |||
[[Category: Synthetic construct]] | |||
[[Category: Alboreggia G]] | |||
[[Category: Assar Z]] | |||
[[Category: Muzzarelli KM]] | |||
[[Category: Pellecchia M]] | |||
Latest revision as of 08:26, 15 May 2024
Histidine-covalent stapled alpha-helical peptide (155H1) targeting hMcl-1Histidine-covalent stapled alpha-helical peptide (155H1) targeting hMcl-1
Structural highlights
FunctionMCL1_HUMAN Involved in the regulation of apoptosis versus cell survival, and in the maintenance of viability but not of proliferation. Mediates its effects by interactions with a number of other regulators of apoptosis. Isoform 1 inhibits apoptosis. Isoform 2 promotes apoptosis.[1] Publication Abstract from PubMedSeveral novel and effective cysteine targeting (Cys) covalent drugs are in clinical use. However, the target area containing a druggable Cys residue is limited. Therefore, methods for creating covalent drugs that target different residues are being looked for; examples of such ligands include those that target the residues lysine (Lys) and tyrosine (Tyr). Though the histidine (His) side chain is more frequently found in protein binding locations and has higher desirable nucleophilicity, surprisingly limited research has been done to specifically target this residue, and there are not many examples of His-targeting ligands that have been rationally designed. In the current work, we created novel stapled peptides that are intended to target hMcl-1 His 252 covalently. We describe the in vitro (biochemical, NMR, and X-ray) and cellular design and characterization of such agents. Our findings further suggest that the use of electrophiles to specifically target His residues is warranted. Histidine-Covalent Stapled Alpha-Helical Peptides Targeting hMcl-1.,Alboreggia G, Udompholkul P, Baggio C, Muzzarelli K, Assar Z, Pellecchia M J Med Chem. 2024 May 2. doi: 10.1021/acs.jmedchem.4c00277. PMID:38695666[2] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||